Table 2.

Responses to pembrolizumab treatment by RECIST 1.1 by central imaging review.

	Patients
	N = 51
ORR, % (95% CI)	16 (7–29)
DCR, % (95% CI)	57 (42–71)
Best overall response, n (%)
Complete response	0
Partial response	8 (16)
Stable disease	21 (41)
Progressive disease	17 (33)
Nonevaluablea	2 (4)
No assessmentb	3 (6)
Time to response, median (range), months	6 (2–13)
DOR, median (range), months	16 (3–24+)

^aOne patient had a post-baseline imaging assessment at Cycle 1 but was counted as nonevaluable due to insufficient time from randomization.

^bNo post-baseline assessment available for response evaluation.